Clearside Biomedical Q3 EPS $(0.15), Inline, Sales $859.00K Beat $160.00K Estimate
Portfolio Pulse from bharat@benzinga.com
Clearside Biomedical (NASDAQ:CLSD) reported Q3 EPS of $(0.15), which was in line with analyst estimates, but represented a 15.38% decrease from the previous year. Sales of $859K significantly exceeded estimates of $160K, marking a 222.93% increase from the same period last year.
November 13, 2023 | 9:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clearside Biomedical reported a Q3 EPS of $(0.15), matching estimates, and a significant sales beat with $859K against the $160K estimate, a 222.93% YOY increase.
The match on EPS estimates indicates stability in financial performance, while the substantial beat on sales estimates and significant year-over-year growth are likely to be viewed positively by investors, potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100